CORRECTING and REPLACING --Merus Provides 2023 Outlook

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today provided its 2023 outlook.